Let’s get into this week’s cup of biotech tea. ☕ If you only have time for one this week, I’d start with #4!
A subcutaneous Alzheimer’s (tau reduction) therapy shows early success ➡️
An investigational peptide-based pain med shows promise in mice ➡️
A neuromodulation headset for depression launches in the U.S. ➡️
Back-to-back voucher sales bring in over $400M for Ultragenyx ➡️
OpenAI solves longstanding Navier-Stokes problem, but is that good? ➡️
Biotech Term of the Week: Allosteric inhibition ➡️
You're not seeing today's full issue because this is a paid-subscriber week. Upgrade to get every issue, every week! ☕
New here? Catch up on last week’s free issue — there is plenty worth reading. See you next week!
Utah biotech: cutting out infection, bottling up resilience, & mapping hidden biology
🗣️This week’s issue is in the usual format but with a slightly different flavor! How come? I spent last Thursday attending Utah’s BioHive Premieres Event and wanted to cover some of the highlights in this week’s newsletter! Salt Lake City may not be the first place that comes to mind when you think of biotech, but it deserves a closer look. With the Un…
